Liquid biopsy, involving the analysis of circulating tumor DNA (ctDNA) and other biomarkers from blood samples, offers a non-invasive method to monitor FGFR2 alterations and treatment response in gastric cancer. The gene discussed is FGFR2; the disease is gastric cancer.